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Background: The literature on the cost-effectiveness of statin drugs in primary prevention of coronary heart
disease is complex. The objective of this study is to compare the disparate results of recent cost-effectiveness
analyses of statins.
Findings: We conducted a systematic review of the literature on statin cost-effectiveness. The four studies that met
inclusion criteria reported varying conclusions about the cost-effectiveness of statin treatment, without a clear
consensus as to whether statins are cost-effective for primary prevention. However, after accounting for each
study’s assumptions about statin costs, we found substantial agreement among the studies. Studies that assumed
statins to be more expensive found them to be less cost-effective, and vice-versa. Furthermore, treatment of low-
risk groups became cost-effective as statins became less expensive.
Conclusions: Drug price is the primary determinant of statin cost-effectiveness within a given risk group. As more
statin drugs become generic, patients at low risk for coronary disease may be treated cost-effectively. Though many
factors must be weighed in any medical decision, from a cost-effectiveness perspective, statins may now be
considered an appropriate therapy for many patients at low risk for heart disease.
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Background
The HMG-CoA reductase inhibitors, or “statins,” are
proven in multiple randomized, controlled, clinical trials
to lower cardiac morbidity and mortality [1]. Statins suc-
cessfully lower LDL cholesterol in most patients, with
substantial reductions in the risk of major coronary
events, such as MI [2], and stroke [3,4]. Statins reduce
mortality in patients with pre-existing coronary disease
[1], but it is unclear if this mortality benefit holds for
primary prevention [3,5]. Statins are generally well-
tolerated and have a low rate of major side effects [6].
Statin trials suggest that the relative risk reduction of
cardiac disease is constant regardless of each patient’s
overall risk [1,7,8]. Therefore, the number needed to
treat is lower in higher-risk groups; more heart attacks* Correspondence: aaron.mitchell@duke.edu
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distribution, and reproduction in any mediumwill be prevented by treating 100 patients at high risk
for disease than at low risk. Accordingly, statins are
more cost-effective in higher-risk groups, since fewer
patients must be treated for each event prevented [9].
Cost-effectiveness analyses (CEAs) have generally found
that statins are cost-effective in secondary prevention,
since patients with established heart disease are at the
greatest risk [10,11]. However, it remains unclear
whether statins are cost-effective when treating healthy
patients without known cardiac disease.
The question of statin use in primary prevention
remains unresolved in the cost-effectiveness literature. A
meta-analysis of CEAs of statins published before 2002
concluded that patients’ cardiac risk was the primary de-
terminant of whether statin treatment was cost-effective,
and that it was unlikely that statins would be cost-
effective for patients with an annual risk of <1% [9].
Conversely, a 2003 review found that statins would likely
be cost-effective for primary prevention in groups with-
out known cardiac disease but with cardiac risk factorsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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price of statins has fallen substantially and will likely
continue to decrease [12], a trend which would be
expected to improve the cost-effectiveness of statins.
The apparent lack of consensus in the literature and the
changing price of statins may create confusion about
whether it is economical to use statins for lower risk
patients.
To address this question in the current US market, we
conducted a systematic review of the literature to deter-
mine when statin therapy becomes cost-effective for low
risk patients.Methods
We conducted a systematic review of the literature of
CEAs of statins (Figure 1). Published studies were identi-
fied by a Pubmed search using the criteria (“HMG CoA
reductase” OR “statin” OR “statins)” AND (“cost effect-
iveness” OR “economic analysis” OR “cost utility)”; the
search was last conducted on January 2, 2011. This
search yielded 365 results. Papers on unrelated topics or
those without primary research were removed. Further
inclusion criteria included: publication since the year
2000, analysis of health costs in the USA, evaluation of
statins in primary as opposed to secondary prevention,
measurement of statin effectiveness by cardiac endpoint
reduction rather than cholesterol lowering, and compari-
son of statins to non-statin therapy (either placebo or
non-statin active therapy). Five studies remained. One
additional study was excluded because it analyzed the ef-
fectiveness of whole drug regimens but not of statins in
isolation, leaving four studies for analysis [12-15].Figure 1 Article selection. Flowchart of article selection.For each study, we determined 1) the presumed price
of statins that each study used in its analysis, and 2) the
resulting incremental cost-effectiveness ratio when treat-
ing patients at multiple Framingham risk levels. As each
paper presented data in a different format, the details of
our data extraction are found in the Additional file 1.
Drug prices and incremental cost-effectiveness ratios
(ICERs) [16] were converted to 2006 dollars using the
consumer price index for medical care. The ICERs
reported by each study were stratified by Framingham
10-year risk of a major coronary event. For each risk
group, ICERs were then expressed as a function of the
drug price. Some studies provided results for a variety of
drug prices, or provided enough data for their results to
be extrapolated to different drug prices; where possible,
we used these different drug price-scenarios as add-
itional data points in our analysis.
Results
Four cost-effectiveness analyses of statin therapy for pri-
mary prevention met inclusion criteria (Table 1). All
studies analyzed health care costs from the health care
system perspective – inclusive of and limited to all direct
medical costs to all payers resulting from the statin ther-
apy. The time horizon varied from as little as 5 years to
lifetime. Annual drug prices varied from $770 to over
$1,500 in 2006 dollars. Models of drug effectiveness
were based on clinical trials of pravastatin in three of the
four studies, and in one on “low intensity” and “high in-
tensity” statin regimens [12]. Two studies segregated
men and women in their analysis, while one analyzed
men only and one studied all persons in aggregate. Stud-
ies compared statins to placebo [13], diet modification
Table 1 Source studies
Study, 1st Author Year Population Drug Studied Time Horizon Outcome Measured
Prosser LA 2000 Age 35-84, LDL >159 Pravastatin 30 years QALY
Caro JJ 2003 Age >45 Pravastatin 5 years LYG
Pignone M 2006 45-year old men Pravastatin Lifetime QALY
Pletcher MJ 2009 Age >35 All statins 30 years QALY
Methodological differences among studies. QALY, quality adjusted life year; LYG, life year gained; LDL, low density lipoprotein cholesterol.
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[12]. Three of the studies assessed cost-effectiveness in
terms of quality-adjusted life year (QALY) gained, and
one measured life years gained (LYG) [13].
The studies offered varying assessments of the cost-
effectiveness of statins (Figure 2). Costs ranged from as
much as $590,000 to as little as $3 to extend life by one
year. The more recent studies found statin therapy more
likely to be cost-effective.
To assess whether these differing conclusions were the
result of the studies’ having modeled patients at different
cardiac risk levels, we compared ICERs within risk
groups. This resulted in greater consistency among the
source studies for patients at 5%, 10%, and 25% 10-year
risk for a major cardiac event by Framingham score.Figure 2 Reported ranges of cost-effectiveness ratios. Reported
range of cost per QALY or LYG for the use of statins for primary
prevention within each study. Also shown is the projected cost per
QALY or LYG for men at average or 7.5% 10-year risk for coronary
disease. Values shown are derived from the “base case” assumptions
of the model used in each study, with the variable being the risk
level of the patient population or the treatment strategy applied. For
Prosser et al., Caro et al., and Pignone et al., these values represent
ranges for men at varying risk levels. For Pletcher et al., these values
represent the cost-effectiveness of statin treatment strategies as
compared to a baseline of standard primary prevention guidelines.
All values adjusted to 2006 dollars. QALY, quality adjusted life year;
LYG, life year gained.Once the varying levels of cardiac risk had been con-
trolled for, the primary factor driving the cost-
effectiveness of statins was the presumed drug price
(Figure 3). There was a direct relationship between the
cost of statins and each study’s conclusions. The cheaper
the statin, the lower its associated ICER. The correlation
between drug price and cost-effectiveness was strong
across the different studies. Within each risk group, the
cost profile improved as the drug price fell.
We confirmed that statin cost-effectiveness increases
with the risk level of the population. Using the $50,000
per QALY threshold, treatment of patients at relatively
higher risk (25% over 10 years) was cost-effective at
higher drug prices than for patients at lower risk. Add-
itionally, it became cost effective to treat patients with a
10% 10 year risk at statin prices under $843.27 per year
(approximately $70 per month), and even patients with a
5% 10 year risk at prices under $604.72 per year (ap-
proximately $50 per month).
Discussion
Within the United States health care system, we found a
strong relationship between drug price and the incre-
mental cost-effectiveness ratio for statin therapy. Our
results support the conclusion that drug cost is the pri-
mary determinant of statin cost-effectiveness.
Our findings are important as they suggest that there
is substantial agreement in the medical literature on sta-
tin cost-effectiveness. The apparently large, unreconciled
discrepancies of previous reports may have made it diffi-
cult for clinicians to draw conclusions about statin cost-
effectiveness, especially for lower risk patients. For ex-
ample, other reviews of statin CEAs found reports of
statin costs ranging from $6,500 to $490,000 per LYG in
low-risk patients [9]. With reported ICERs varying by
orders of magnitude, these results seemingly indicate a
lack of consensus on the cost-effectiveness of these
drugs.
Our analysis suggests a resolution of this dilemma. We
demonstrate that after controlling for patient risk level
and drug cost, these studies appear to agree. This
consistency is supported by one author who noted that
the differences between his findings and those of an earl-
ier study [14] may have been the result of “lower esti-
mates for the pill costs of statins” [12]. Rather than the
Figure 3 Cost-effectiveness ratios for patients at specific risk levels. Incremental cost-effectiveness ratios, shown on the y-axis, were
extracted from each article and grouped by 10-year Framingham cardiac risk levels. Within each risk level, the cost-effectiveness of statin
treatment was compared with the presumed annual price of statin drugs from each study. Linear regression analysis using Excel spreadsheet
function is also shown. QALY, quality adjusted life year; LYG, life year gained.
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ure 2), it seems that there is agreement in the cost-
effectiveness literature on statins.
Our results have implications for the use of statins in
clinical practice. As statin ICERs improve as drug prices
fall, from a cost perspective it will eventually become ap-
propriate to treat very low-risk patients. For example,
under ATP-III guidelines, a healthy individual with a 10-
year risk for heart attack or cardiac death of 5% would
not receive pharmacologic treatment unless his LDL
exceeded 190 g/dL, whereas our results imply that it
would be cost-effective to treat this patient if statins
could be obtained for less than $604.72 per year. Our
conclusions are consistent with those of Pletcher et al.,
that “with lower costs, extending statin therapy to larger,
lower-risk segments of the U.S. population becomes
cost-effective [12].” From a cost perspective, treatment
decisions should not be made categorically based on
strict criteria, but by an evaluation of each patient’s risk
level as well as the current drug availability. It should be
noted that treating patients based purely on an evalu-
ation of cost-effectiveness would mean extending statin
therapy beyond current treatment guidelines.
If drug costs are part of the treatment calculus, then
health care providers need to be familiar with the pre-
vailing prices in their communities. Where in this
spectrum of high costs and targeted treatment vs. low
costs and extended treatment do we currently lie? Are
the low drug prices necessary to treat a 5%-risk patient
cost-effectively still far in the future, or have they already
come to pass? Pletcher et al., published in 2006, esti-
mated the annual cost for low-intensity statins at $770
[12]. Since then, prices for generic simvastatin have
already fallen by 60% [17]; our results predict that at this
price it would be cost-effective to treat patients at 5%
10-year risk. Others have found that at prices below$0.10 per pill, it becomes not only cost-effective but
cost-saving to treat adults at all risk levels [12]; the avail-
able prices at some large retailers in the USA have
already passed this threshold [18]. At these low prices,
our analysis supports the conclusion that it is cost-
effective to treat more Americans with statins than
would qualify for pharmacologic cholesterol reduction
under current guidelines.
Demographically, what does a patient at a 5% Fra-
mingham risk level look like? As an example, any male
smoker over the age of 50, even one with favorable
blood pressure and lipid profiles, has a 10-year risk of
greater than 5%. Furthermore, even the lowest-risk male
over age 60 exceeds the 5% risk level [19]. Our results
indicate that it may be cost-effective to treat both of
these hypothetical patients with statins.
Limitations
Our study pertains only to primary prevention: patients
with no history of coronary disease. Indeed, statins are
far more cost-effective in secondary prevention, and the
benefits of their usage in this context have been well-
established in the cost-effectiveness literature [12]. It
would be a mistake to withhold statin therapy from a
post-MI patient, for example, because statins were not
obtainable at the prices discussed in this study, as our
incremental cost-effectiveness ratios are applicable only
to primary prevention.
Importantly, each study we reviewed assessed only the
direct medical costs of patient care. While this is stand-
ard practice for cost-effectiveness analyses, it excludes
secondary economic costs to society such as losses in
worker productivity. These costs can potentially be very
large, and when they are factored into the analysis sta-
tins become more cost-effective, and possibly cost-
saving, across many scenarios [20].
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mary prevention setting would be expected to increase
overall health care costs. Use of these drugs in additional
low-risk patients may be, as our analysis suggests, a
cost-effective intervention; however, this would require
the dedication of significant health care resources [10].
Head-to-head comparison of individual statin drugs
was beyond the scope of our study. It was assumed that
the benefits of statins are proportional to their lipid-
lowering effects, and therefore that the same cholesterol
reduction obtained by different doses of different agents
will yield similar results. As statins currently vary widely
in price, it is to be expected that different degrees of
lipid lowering (and consequently different degrees of
cardiac protection) would be achievable with the same
health care dollar depending upon which agent is
chosen. This is an assumption, however, and the fact
that 3 of the 4 studies based their models on data
derived from pravastatin trials may limit the
generalizability of our findings to other statins.
The most important assumption of our sources is that
the relative risk reduction achieved with statins is con-
stant across primary prevention subgroups, including
low risk patients. This assumption is not universally
accepted [10]. In addition, our source studies assumed
statins to be safe, with negligible costs associated with
any rare, adverse drug reactions. One source study expli-
citly included the health care costs of statin-associated
adverse events such as myopathy, and concluded that
these events are rare enough to have a negligible effect
on incremental cost-effectiveness ratios [15]. Based on
the available clinical trial and epidemiologic literature,
we believe these assumptions are valid.
Our conclusions are not affected by a recent Cochrane
meta-analysis emphasizing “caution” in the use of statins
in primary prevention [21]. This meta-analysis agreed
with previously reported estimates of the benefits of sta-
tins in primary prevention – an approximately 30% re-
duction in combined fatal and non-fatal cardiovascular
events. Since the studies we analyzed herein used similar
estimates in generating their cost-effectiveness data,
their results are in line with the statin benefits outlined
by the Cochrane meta-analysis. This meta-analysis also
found no increased rate of any adverse event in patients
receiving statin therapy for primary prevention, includ-
ing myalgia, rhabdomyolysis, or cancer, supporting the
supposition that the management of adverse events has
little, if any, effect on statin cost-effectiveness. Regard-
less, the recommendation for caution was due to a con-
cern that adverse events may have been under-reported
in statin clinical trials.
Our conclusions differ from those of a recent cost-
effectiveness analysis [22]. Its results suggest poor statin
cost-effectiveness even when assuming very low drugcosts, though its focus on the Swiss health care system
makes direct comparison to our US-based analysis diffi-
cult. This disagreement is most likely due to several
methodological differences that were not shared by our
source studies. The authors assume that 1) disadherence
to statin therapy is high and 2) there is a small but
measurable disutility caused by taking medication, and
3) they assessed costs and benefits over 10 years rather
than patient lifetime. Each of these factors significantly
decreased statin cost-effectiveness in sensitivity analysis.
Particularly, while the authors assume 60% disadherence
to statin therapy after 3 years [22], only one of the stud-
ies included in our analysis factored significant disadher-
ence in its model [13], while the other three assumed
95–100% adherence; this difference would make statin
therapy appear more favorable in the studies we
analyzed.
The methodological differences among our source
studies might limit direct comparison of their results.
Comparing statins to a baseline therapy such as aspirin
or diet might make statins appear less cost-effective if
the baseline therapy is efficacious and relatively cheap,
since in comparison statins will prevent relatively fewer
cardiac events for the same cost. Measuring costs and
benefits over a longer time period may improve cost-
effectiveness, because life-years saved will have a greater
chance to accrue, especially for younger populations.
Measurement of QALY instead of LYG may be expected
to reduce cost-effectiveness, since elderly patients, for
whom statins will prevent the most cardiac events, are
usually assumed to have a lower quality of life due to
disability.
In summary, we found a strong correlation between
drug price and cost-effectiveness for healthy patients at
varying risk for coronary disease. Statin therapy should
be increasingly more cost-effective for lower-risk
patients as drug prices decline. Based on cost-
effectiveness, it would be reasonable for clinicians to be
more aggressive in treating low-risk patients, and for fu-
ture treatment guidelines to consider recommending
therapy for a broader patient base.Additional file
Additional file 1: Additional details of data extraction from source
studies.Abbreviations
LDL: Low density lipoprotein; ICER: Incremental cost-effectiveness ratio;
CEA: Cost-effectiveness analysis; QALY: Quality adjusted life year; LYG: Life
year gained.Competing interests
APM: none
Mitchell and Simpson BMC Research Notes 2012, 5:373 Page 6 of 6
http://www.biomedcentral.com/1756-0500/5/373RJS: Consultancies: (Merck, Pfizer, Liposcience); Speaking engagements: (Merck,
Pfizer); Salary support: (Carolina Center for Medical Excellence); Research
grants: (Merck)Authors’ contributions
APM: Conceived of the study, conducted literature review and statistical
analysis, and drafted the manuscript. RJS: Guided study design and scope,
revised and edited the manuscript. All authors read and approved the final
manuscript.Acknowledgements
This work had no sponsor, and its results were not approved for publication
by any other parties.
Author details
1Duke University Medical Center, Medical Residency Office Rm 8254DN, 2301
Erwin Rd, Durham, NC 27710, USA. 2Department of Cardiology, UNC-Chapel
Hill School of Medicine, 101 Manning Drive, Chapel Hill, NC 27514, USA.
Received: 1 February 2012 Accepted: 3 July 2012
Published: 24 July 2012References
1. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease:
a meta-analysis of randomized controlled trials. JAMA 1999,
282(24):2340–2346.
2. Brugts JJ, Deckers JW: Statin prescription in men and women at
cardiovascular risk: to whom and when? Curr Opin Cardiol 2010, 25
(5):484–489.
3. Brugts JJ, Yetgin T, Hoeks SE, et al: The benefits of statins in people
without established cardiovascular disease but with cardiovascular risk
factors: meta-analysis of randomised controlled trials. BMJ 2009, 338:
b2376.
4. Amarenco P, Labreuche J: Lipid management in the prevention of stroke:
review and updated meta-analysis of statins for stroke prevention.
Lancet Neurol 2009, 8(5):453–463.
5. Ray KK, Seshasai SRK, Erqou S, et al: Statins and all-cause mortality in high-
risk primary prevention: a meta-analysis of 11 randomized controlled
trials involving 65,229 participants. Arch Intern Med 2010,
170(12):1024–1031.
6. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341
(7):498–511.
7. Mihaylova B, Briggs A, Armitage J, et al: Cost-effectiveness of simvastatin
in people at different levels of vascular disease risk: economic analysis of
a randomised trial in 20,536 individuals. Lancet 2005,
365(9473):1779–1785.
8. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease
with pravastatin in men with hypercholesterolemia. West of Scotland
Coronary Prevention Study Group. N Engl J Med 1995, 333(20):1301–1307.
9. Franco OH, Peeters A, Looman CWN, Bonneux L: Cost effectiveness of
statins in coronary heart disease. J Epidemiol Community Health 2005, 59
(11):927–933.
10. Ward S, Lloyd Jones M, Pandor A, et al: A systematic review and economic
evaluation of statins for the prevention of coronary events. Health
Technol Assess 2007, 11(14):1–160. iii–iv.
11. Morrison A, Glassberg H: Determinants of the cost-effectiveness of statins.
J Manag Care Pharm 2003, 9(6):544–551.
12. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al: Comparing impact and
cost-effectiveness of primary prevention strategies for lipid-lowering.
Ann Intern Med 2009, 150(4):243–254.
13. Caro J, Huybrechts KF, Klittich WS, Jackson JD, McGuire A: Allocating funds
for cardiovascular disease prevention in light of the NCEP ATP III
guidelines. Am J Manag Care 2003, 9(7):477–489.
14. Prosser LA, Stinnett AA, Goldman PA, et al: Cost-effectiveness of
cholesterol-lowering therapies according to selected patient
characteristics. Ann Intern Med 2000, 132(10):769–779.
15. Pignone M, Earnshaw S, Tice JA, Pletcher MJ: Aspirin, statins, or both drugs
for the primary prevention of coronary heart disease events in men: a
cost-utility analysis. Ann Intern Med 2006, 144(5):326–336.16. Evans C, Tavakoli M, Crawford B: Use of quality adjusted life years and life
years gained as benchmarks in economic evaluations: a critical appraisal.
Health Care Manag Sci 2004, 7(1):43–49.
17. Curtiss FR, Fairman KA: Tough questions about the value of statin therapy
for primary prevention: did JUPITER miss the moon? J Manag Care Pharm
2010, 16(6):417–423.
18. Findlay S: The statin drugs: prescription and price trends, October 2005 to
December 2006.: Consumers Union; 2007. Available at: www.
consumerreports.org/health/resources/pdf/best-buy-drugs/Statins-RxTrend-
FINAL-Feb2007.pdf.
19. Wilson PW, D’Agostino RB, Levy D, et al: Prediction of coronary heart
disease using risk factor categories. Circulation 1998, 97(18):1837–1847.
20. Grover SA, Ho V, Lavoie F, et al: The importance of indirect costs in
primary cardiovascular disease prevention: can we save lives and money
with statins? Arch Intern Med 2003, 163(3):333–339.
21. Taylor F, Ward K, Moore TH, et al: Statins for the primary prevention of
cardiovascular disease. Cochrane Database Syst Rev 2011, 1:CD004816.
22. Greving JP, Visseren FLJ, de Wit GA, Algra A: Statin treatment for primary
prevention of vascular disease: whom to treat? Cost-effectiveness
analysis. BMJ 2011, 342:d1672.
doi:10.1186/1756-0500-5-373
Cite this article as: Mitchell and Simpson: Statin cost effectiveness in
primary prevention: A systematic review of the recent cost-effectiveness
literature in the United States. BMC Research Notes 2012 5:373.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
